Core Viewpoint - Alcon (ALC) is expected to report quarterly earnings of $0.79 per share, a 9.7% increase year-over-year, with revenues projected at $2.71 billion, reflecting a 9.3% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised upward by 1.5% over the past 30 days, indicating analysts' reappraisal of their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Key Metrics Projections - Analysts project 'Net Sales- Total Surgical- Equipment/other' to be $277.54 million, a 21.2% increase from the prior-year quarter [5]. - 'Net Sales- Total Surgical- Implantables' is expected to reach $482.10 million, indicating a 5.7% year-over-year change [5]. - The estimate for 'Net Sales- Total Surgical' is $1.56 billion, reflecting a 9.3% increase year-over-year [5]. - 'Net Sales- Total Vision care' is projected at $1.15 billion, a 9.1% increase from the previous year [6]. - 'Net Sales- Total Surgical- Consumables' is expected to be $796.13 million, indicating a 7.9% year-over-year change [6]. - The consensus for 'Net Sales- Total Vision Care- Contact lenses' stands at $687.14 million, reflecting a 7.7% increase [6]. - 'Net Sales- Total Vision Care- Ocular health' is projected to reach $462.70 million, a change of 11.2% from the prior-year quarter [7]. - 'Net Sales and other revenues- Other revenues' is estimated at $26.18 million, suggesting a 4.7% year-over-year change [7]. Stock Performance - Over the past month, Alcon shares have returned +0.8%, while the Zacks S&P 500 composite has changed by -0.8% [7]. - Alcon holds a Zacks Rank 3 (Hold), indicating that its performance is expected to align with the overall market in the upcoming period [7].

The Cooper Companies (COO), headquartered in San Ramon, California, develops, manufactures, and markets contact lens wearers. Valued at $16.3 billion by market cap, the company’s products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians. Shares of this global medical device company have underperformed the broader market over the past year. COO has declined 7% over this time frame, while the broader S&P 500 ...

Company Overview - Cooper Companies was founded in 1958 and has been listed on the S&P 500 since 2016 [1] - The company operates under two main business units: CooperVision and CooperSurgical [1] - CooperVision is the leading contact lens company globally, ranked 1 in terms of wearers and 2 in revenue [1] - CooperSurgical specializes in fertility and women's health care, focusing on non-pharmaceutical medical devices [1] Employee and Market Reach - The company employs over 15,000 individuals worldwide [2] - More than 50 million people use Cooper's products, including contact lenses and women's health care products [2] - Approximately 42 million patients annually wear Cooper's contact lenses [2] - CooperVision accounts for about two-thirds of the company's consolidated revenues [2]

Company Overview - Warby Parker Inc. is a vertically integrated eyewear company focused on accessible, design-driven products and a seamless omnichannel experience, leveraging both physical retail and digital channels to reach a broad customer base [7] - The company offers prescription eyeglasses, sunglasses, contact lenses, and vision care accessories, generating revenue primarily from eyewear sales and related services [10] Recent Transaction Details - Co-Chief Executive Officer David Abraham Gilboa sold 94,906 shares for approximately $2.6 million at a weighted average price of $27.51 per share on January 7 and 9, 2026, which represents 71.82% of his direct equity stake [4][5] - Following the transaction, Mr. Gilboa's direct equity stake fell to 37,247 shares, valued at about $1.1 million as of January 9, 2026 [2][5] - The shares were sold at a slight discount to the market price, which was $29.09 as of January 13, 2026 [1] Financial Performance - Warby Parker's third quarter revenue grew 15% year over year to $221.7 million, with a net income of $5.9 million, a significant improvement from a net loss of $4.1 million in the previous year [11] Market Context - The stock reached a 52-week high of $31 on December 11, 2025, following the announcement of AI-powered eyeglasses, indicating strong market interest [8] - The forward price-to-earnings ratio of 62 suggests that the stock may be overvalued, indicating a potential selling opportunity for current shareholders [12] Insider Trading Mechanism - Mr. Gilboa's stock sale was part of a prearranged Rule 10b5-1 trading plan adopted in September 2025, which is commonly used by insiders to avoid accusations of insider trading [9]

J.P. Morgan Healthcare Conference David J. Endicott Chief Executive Officer January 13th, 2026 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," ...

Core Insights - Warby Parker, a direct-to-consumer eyewear company, reported a significant insider sale by co-CEO David Abraham Gilboa, who sold 94,906 shares valued at $2.61 million [1][2][8] Company Overview - Warby Parker generated $850.58 million in revenue over the trailing twelve months (TTM) and reported a net income of $717,000 [4] - The company's stock price increased by 11.77% over the past year, although it lags behind the S&P 500, which rose approximately 18% during the same period [8] Transaction Details - The insider sale involved the conversion and sale of derivative securities under a pre-established Rule 10b5-1 trading plan, indicating planned monetization rather than opportunistic trading [5][8] - Post-transaction, Gilboa retains 37,247 shares, representing 0.03% of the outstanding shares, while still holding significant exposure through derivative securities [5][8] Operational Performance - Warby Parker's third-quarter revenue increased by 15% year-over-year to $221.7 million, with net income rising to $5.9 million from a loss in the previous year [9] - Adjusted EBITDA reached $25.7 million, resulting in a margin of 11.6%, and the number of active customers grew by over 9% on a trailing twelve-month basis [9] Market Position - The company operates a vertically integrated model, controlling costs and delivering value through both physical stores and online platforms, targeting value-conscious consumers in the U.S. and Canada [6][7]

Core Insights - Warby Parker has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and a price target of $26.75 [1] - The company's stock has experienced a decline of 8.1% recently, with a market cap of $2.56 billion and a high price-to-earnings ratio of 2,418.60 [2] - Warby Parker reported quarterly earnings of $0.06 per share, missing estimates, with revenue of $221.68 million, a 15.2% increase year-over-year [3] Analyst Ratings - Weiss Ratings maintained a "hold (c-)" rating [1] - UBS Group lowered its price target from $23.00 to $20.00, maintaining a "neutral" rating [1] - Piper Sandler raised its target price from $22.00 to $32.00, giving an "overweight" rating [1] - BTIG Research increased its target price from $25.00 to $32.00, issuing a "buy" rating [1] - Citizens Jmp upgraded from "market perform" to "outperform" with a $30.00 price target [1] Financial Performance - The company reported earnings per share of $0.06, missing the consensus estimate of $0.09 by $0.03 [3] - Revenue for the quarter was $221.68 million, below the expected $224.49 million [3] - Year-over-year revenue growth was 15.2% [3] Insider Activity - Director Joel E. Cutler sold 19,932 shares at an average price of $26.01, reducing his position by 49.91% [4] - Director Youngme E. Moon sold 38,832 shares at an average price of $29.07, decreasing ownership by 58.94% [4] - In total, insiders sold 158,764 shares valued at $4,676,278 over the last three months [4] Institutional Holdings - Institutional investors own 93.24% of Warby Parker's stock [7] - Man Group plc increased its holdings by 1.6%, now owning 25,095 shares worth $550,000 [5] - Choreo LLC grew its position by 4.6%, owning 16,605 shares valued at $458,000 [5] - Ameritas Investment Partners Inc. increased its stake by 8.3%, now holding 10,034 shares worth $220,000 [7] Company Overview - Warby Parker, founded in 2010, is a U.S.-based eyewear company that sells prescription glasses, sunglasses, and contact lenses through a direct-to-consumer model [8][9] - The company integrates online and brick-and-mortar channels, offering features like virtual try-on technology and a home try-on program [8]

Core Viewpoint - Bausch + Lomb Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference, highlighting its commitment to eye health and innovation [1]. Group 1: Company Presentation - The presentation will feature Chairman and CEO Brent Saunders, Executive Vice President and CFO Sam Eldessouky, and Chief Medical Officer Yehia Hashad, MD [1]. - The event is scheduled for January 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) [1]. Group 2: Investor Relations - A live webcast and audio archive of the event will be accessible on the Investor Relations page of the Bausch + Lomb website [2]. Group 3: Company Overview - Bausch + Lomb has a mission to help people see better to live better, with a history of nearly two centuries in evolving to meet patient and customer needs [3]. - The company focuses on innovation and improving standards of care in eye health, offering a range of products from contact lenses to surgical devices [3].

Core Insights - National Vision (EYE) has experienced a significant share price increase of 154.6% over the past 12 months, outperforming the industry decline of 13.9% and the S&P 500's growth of 16.4% [1][9] Company Performance - National Vision holds a Zacks Rank 3 (Hold) and is benefiting from the strong performance of its America's Best brand, with strategic initiatives showing early progress [2] - The company operates 1,242 retail stores across four brands and has a distribution network that includes a 118,000-square-foot center in Georgia and a 52,000-square-foot center in Ohio [3] Revenue Growth - The Owned & Host segment of National Vision reported a 9.1% year-over-year revenue increase in Q3 2025, primarily driven by America's Best brand [4][9] - The company opened four new America's Best stores and converted four Eyeglass World locations during the September 2024 to September 2025 period [5] Strategic Initiatives - National Vision is enhancing its Eyeglass World operations with a new leadership team and expanding remote exam capabilities, with two-thirds of its stores now equipped for remote technology [6] - The company is testing smaller store formats for America's Best and is incorporating insights from a fleet optimization review into future growth plans [5][6] Customer Engagement - Early indicators of stronger customer engagement are noted, supported by a new marketing strategy and customer relationship management (CRM) platform [10] - Newly introduced premium frames are selling faster than expected, indicating positive consumer response [10] Financial Estimates - The Zacks Consensus Estimate projects a 32.6% increase in earnings per share (EPS) for 2025, reaching $0.69, and a 26.8% increase for 2026, reaching $0.88 [12] - Revenues are expected to grow by 5.2% to $1.98 billion in 2025 and reach $2.05 billion in 2026, implying a 3.3% increase [12]

Company Overview - Bausch + Lomb Corporation is a global leader in eye health, operating across vision care, pharmaceuticals, and surgical segments, leveraging a diverse product portfolio and international distribution to address a wide range of ocular conditions and procedures [8] - The company generates revenue primarily through the sale of proprietary and generic eye health products to healthcare professionals, clinics, and retail channels worldwide, serving ophthalmologists, optometrists, surgical centers, and consumers seeking vision correction and eye health solutions globally [12] Financial Performance - For the third quarter, Bausch + Lomb reported revenue of $1.28 billion, reflecting a 7% year-over-year increase, driven by growth across its Vision Care, Pharmaceuticals, and Surgical segments [9] - Adjusted EBITDA for the same quarter rose to $243 million, up from $212 million a year earlier, with management increasing full-year adjusted EBITDA guidance, indicating confidence in execution despite external challenges [9] Market Position and Stock Performance - As of the latest report, Bausch + Lomb's stock price was $15.69, down 9% over the past year, which is significantly below the S&P 500's 12% gain [4][5] - The company's stock remains volatile, and the recent full exit by DSC Meridian Capital suggests a lower conviction in the healthcare-specific investment compared to the fund's other holdings in infrastructure and commodity-linked sectors [10] Investment Sentiment - Bausch + Lomb is not considered a turnaround story but shows signs of durability with a diversified revenue base, expanding product pipeline, and improving profitability [11] - The risk associated with the company is less about its fundamentals and more about market sentiment, as investors have been quick to trade around volatility rather than hold [11]